This is the authors' abstract. We don't add key points for this paper.
This exploratory dose-finding study showed that a single administration of remimazolam (0.10-0.20 mg/kg) was capable of inducing rapid sedation with a quick recovery profile in patients undergoing a diagnostic upper gastrointestinal endoscopy. The safety profile was favorable and appeared to be similar to that of midazolam, warranting further development of this short-acting compound.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Borkett et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: